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Abstract
Background: Poor methodological quality and reporting are known concerns with diagnostic accuracy studies. In 2003, the
QUADAS tool and the STARD standards were published for evaluating the quality and improving the reporting of diagnostic
studies, respectively. However, it is unclear whether these tools have been applied to diagnostic studies of infectious
diseases. We performed a systematic review on the methodological and reporting quality of diagnostic studies in TB,
malaria and HIV.
Methods: We identified diagnostic accuracy studies of commercial tests for TB, malaria and HIV through a systematic search
of the literature using PubMed and EMBASE (2004–2006). Original studies that reported sensitivity and specificity data were
included. Two reviewers independently extracted data on study characteristics and diagnostic accuracy, and used QUADAS
and STARD to evaluate the quality of methods and reporting, respectively.
Findings: Ninety (38%) of 238 articles met inclusion criteria. All studies had design deficiencies. Study quality indicators that
were met in less than 25% of the studies included adequate description of withdrawals (6%) and reference test execution
(10%), absence of index test review bias (19%) and reference test review bias (24%), and report of uninterpretable results
(22%). In terms of quality of reporting, 9 STARD indicators were reported in less than 25% of the studies: methods for
calculation and estimates of reproducibility (0%), adverse effects of the diagnostic tests (1%), estimates of diagnostic
accuracy between subgroups (10%), distribution of severity of disease/other diagnoses (11%), number of eligible patients
who did not participate in the study (14%), blinding of the test readers (16%), and description of the team executing the test
and management of indeterminate/outlier results (both 17%). The use of STARD was not explicitly mentioned in any study.
Only 22% of 46 journals that published the studies included in this review required authors to use STARD.
Conclusion: Recently published diagnostic accuracy studies on commercial tests for TB, malaria and HIV have moderate to
low quality and are poorly reported. The more frequent use of tools such as QUADAS and STARD may be necessary to
improve the methodological and reporting quality of future diagnostic accuracy studies in infectious diseases.
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Introduction
Tuberculosis (TB), malaria and human immunodeficiency virus
(HIV), the ‘big three’ among infectious diseases, are major global
causes of morbidity and mortality. Together, they cause more than
3.5 million deaths per year.[1,2,3] Consequently, considerable
financial and other investments have been directed towards the
control of these diseases in recent years, which includes the
development of diagnostic and treatment services that are
accessible to patients. For example, the Global Fund to Fight
AIDS, TB and Malaria has committed US$ 15.6 billion in 140
countries to support large-scale prevention, treatment and care
programs against these three diseases.[4]
Recently, simple and robust technological platforms that allow
rapid diagnostic testing at the primary health care level have
greatly increased diagnostic capability, particularly in developing
countries. The use of such tests for HIV is well-established, and the
use of rapid diagnostic tests (RDT) in malaria control programmes
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not been successful, the WHO has recently endorsed the use of
two new diagnostic technologies for TB and drug-resistance, and
several other new TB diagnostics are in the pipeline. [7,8,9,10]
The increasing number of diagnostic tests for TB, malaria and
HIV leaves regulatory authorities, policy makers and health care
professionals with the difficult task of choosing the tests that would
best fit their patientpopulations and health-care delivery systems. In
order to make evidence-based decisions, they often use published
diagnostic accuracy studies as a way of gathering evidence about
their options. [8] Also, the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach to
guideline development requires a careful assessment of evidence on
diagnostic accuracy, as well as other considerations, such as patient-
important outcomes, the overall quality of evidence across these
outcomes and the balance between benefits and harms and the
strength of recommendations. [11,12] However, systematic reviews
have revealed that the value of diagnostic accuracy studies is
frequently compromised by poor methodological quality and/or
poor reporting.[13,14,15] There is also a growing realization that
design flaws can systematically bias estimates of diagnostic
accuracy.[16,17,18] Furthermore, even diagnostic test accuracy
data may not be sufficient for policy making, because they are
surrogates for patient-important outcomes.[12]
In 2003, two tools were developed with the objective of
providing researchers with a standardized and validated format for
assessing quality of diagnostic studies and a template for improving
reporting: QUADAS (Quality Assessment of Studies of Diagnostic
Accuracy) and STARD (STAndards for the Reporting of
Diagnostic accuracy studies).[19,20,21] QUADAS was designed
to be used in systematic reviews to evaluate the quality of primary
diagnostic accuracy studies, while STARD was developed to
improve the quality of reporting of diagnostic accuracy studies in
general.
Both tools are slowly gaining acceptance in the diagnostic
literature. In April 2008, it was estimated that more than 200
biomedical journals encouraged the use of the STARD statement
in their instructions for authors.[22] The QUADAS tool is
increasingly being used in diagnostic accuracy meta-analyses.
However, it is unclear if these tools have been widely accepted and
applied to diagnostic accuracy studies of major infectious diseases.
We performed a systematic review with the objective to describe
the methodological and reporting quality of recently published
diagnostic accuracy studies on commercial tests for TB, malaria
and HIV.
Methods
Search Strategy
We searched PubMed and EMBASE (OVID interface) for
primary diagnostic accuracy studies published between January
2004 and December 2006. We chose these databases because
together they have a wide coverage of the health literature and
would therefore enable us to obtain a fairly representative sample
of indexed diagnostic studies published in the time period of
interest. We limited the search to the period between 2004 and
2006 because we wanted to determine the methodological and
reporting quality of diagnostic studies following the publication
and dissemination of QUADAS and STARD.
The keywords and search terms that were used included
{[‘tuberculosis’ (explode) OR ‘Mycobacterium tuberculosis’ (explode)
OR ‘(tuberculosis or tuberculous).ti’] OR [‘malaria’ (explode) OR
‘Plasmodium’ (explode) OR ‘malaria.ti’] OR [‘HIV’ (explode)
OR ‘HIV seropositivity’ (explode) OR ‘HIV infections’ (explode)
OR ‘acquired immunodeficiency syndrome’ (explode) OR
‘HIV.ti’]} AND [‘sensitivity and specificity’ (explode) OR ‘specifi-
city.ti’ OR ‘specificity.ab’ OR ‘accuracy.ti’ OR ‘diagn$.ti’]}.
The search was limited to studies in humans.
Study Eligibility
We included diagnostic accuracy studies on commercial tests for
TB, malaria and HIV that aimed to determine sensitivity and
specificity of a given diagnostic test for one of these three
infections. To be eligible, the studies had to be original, describe
their methods, report sensitivity and specificity data and be
published between January 2004 and December 2006. Languages
were restricted to English, French, Spanish and Portuguese
(languages that our study team was able to cover). Because
commercial tests are standardized and usually test methods are
well reported and easily defined, we restricted the study to
commercial kits. In addition, commercial tests are more likely to
be used in routine clinical practice than exclusively for research.
Study Selection
Initially, one reviewer (PSF) screened the titles and abstracts of
the citations retrieved by the electronic search (first screen).
Citations that were identified as diagnostic accuracy studies were
classified according to the disease (TB, malaria or HIV).
One researcher (PSF) reviewed the full text of all potentially
eligible studies. A second researcher (NPP) independently reviewed
20% of all full text articles considered relevant in the first screen.
Disagreements among reviewers were resolved by consensus.
Figure 1 describes the study selection process.
Data Abstraction
Two researchers (MP and PSF) created a data extraction form
to be used in this review. The initial form was piloted by two
reviewers (PSF and NPP) with 5% of the included publications.
Based upon experience gained in the pilot, we modified and
finalized the data extraction form.
Data extracted only included information explicitly stated in the
text. Data retrieved included the following: year of publication,
journal, disease of interest, type of commercial diagnostic test,
reference standard employed, and data on quality of methods and
reporting (listed below). When data were unavailable or not stated
explicitly, the reviewers coded the information as ‘‘not reported’’.
Any remaining disagreements were resolved by consensus before
finalizing the data extraction.
Assessment of Methodological Quality
We assessed the methodological quality of studies using
QUADAS.[20,21] QUADAS is a validated quality checklist
composed of 14 items, which encompass the most important
sources of bias and variation observed in diagnostic accuracy
studies. It was developed using a Delphi procedure which was used
to reduce an initial list of 28 quality items.
The quality assessment items included in QUADAS are:
spectrum composition, description of selection criteria and
reference standard, disease progression bias, partial and differential
verification, incorporation bias, description of index and reference
test execution, test and reference standard review bias, clinical
review bias, and description of uninterpretable test results. The
definition of the items listed above can be found in Table 1. All the
researchers involved in data extraction (PSF and NPP) were trained
in the use of QUADAS checklist. Each item in the QUADAS
checklist was scored as ‘‘Yes’’, ‘‘No’’, or ‘‘Unclear’’, as per the
recommendations of the authors of the QUADAS checklist.
Quality of Diagnostic Studies
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The quality of the reporting was evaluated using the STARD
criteria.[19] STARD, developed by a group of scientists and
editors, consists of a checklist of 25 items that assess the
completeness of reporting in diagnostic studies, potential sources
of bias and generalizability. The checklist is subdivided in 5
sections: title/abstract/keywords, introduction, methods, results,
and discussion. The majority of items in the STARD checklist
were scored as ‘‘Not reported’’ or ‘‘Reported’’. The ‘‘Reported’’
category included both ‘‘Fully reported’’ and ‘‘Partially reported’’
sub-categories. A ‘‘Partially reported’’ item means that the authors
mentioned the item, but did not provide all the information
required by the STARD checklist about it.
Three STARD items were scored using other criteria: the item
‘‘participant recruitment’’ was scored as ‘‘recruitment based on
symptoms’’ or ‘‘other recruitment/unclear’’, while the item
‘‘participant sampling’’ was classified as ‘‘consecutive sampling’’
or ‘‘other sampling strategy/unclear’’. Finally, the item ‘‘data
collection’’ was scored as ‘‘prospective’’ and ‘‘retrospective’’.
Eight out of the 25 STARD reporting items were considered
essential by our group for the purposes of our project: reporting of
the sampling strategy used, reference standard test, data collection
Figure 1. Flow diagram for study selection.
doi:10.1371/journal.pone.0007753.g001
Table 1. Biases in diagnostic accuracy test studies.
Bias Definition
Spectrum composition bias When the spectrum of patients is not representative of the patients who will receive the test in practice
Disease progression bias When the time period between reference standard and index test is not short enough to be reasonably sure that the target
condition did not change between the two tests
Partial verification bias When the whole sample or a random selection of the sample does not receive verification using a reference standard of diagnosis
Differential verification bias When patients receive different reference standard depending on the index test result
Incorporation bias When the reference standard is not independent of the index test, i.e., when the index test forms part of the reference standard
Test review bias When the index test results are interpreted with knowledge of the results of the reference standard
Reference standard review bias When the reference standard test results are interpreted with knowledge of the results of the index test
Clinical review bias When test results are interpreted in the light of the clinical data that would not be available when the test is used in practice
Adapted from: Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy
included in systematic reviews. BMC Medical Research Methodology 2003;3:25.
doi:10.1371/journal.pone.0007753.t001
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participate in the study, inclusion and exclusion criteria,
participant recruitment and description of clinic and demographic
characteristics of the study population. These items were used to
compare the quality of reporting of studies after stratifying them
by disease (TB, Malaria and HIV).
Use of STARD
In order to determine the frequency of use of STARD in
diagnostic accuracy studies, we searched the full-text of all the
included papers for any explicit mention of their use by the authors.
Furthermore, in September 2008, we accessed the sections
containing ‘‘information for the authors’’ (author guidelines) on
the websites of all the journals (46 in all) in which the included
papers were published. In doing so, we wanted to determine if the
use of STARD was required when submitting a diagnostic accuracy
manuscript to these journals.
Data Synthesis and Statistical Analysis
Descriptive statistics were used to summarize the number and
proportion of included studies that met the QUADAS and
STARD criteria. We carried out a qualitative synthesis of the
study characteristics, and quality of the methodology and
reporting. Since the studies were heterogeneous with respect to
diseases (TB, malaria and HIV), we decided to present overall
results, as well as results stratified by disease subgroup. We also
stratified the results by year of study publication in order to
capture any temporal change since the publication of the STARD
and QUADAS guidelines.
Results
Study Selection
We identified a total of 3,529 potentially relevant citations from
the database searches. After the first and second screens, a total of
90 full-text studies were eligible for inclusion in this systematic
review (Figure 1).
Description of Included Studies
The characteristics of the included studies are shown in Table 2.
Most papers were published in 2004 (47%). The 90 studies
included were published in 46 different medical journals, Fifty
percent evaluated TB diagnostic tests, 21% malaria diagnostic
tests, and 29% HIV diagnostic tests.
Use of STARD
No study explicitly mentioned using STARD for preparing the
manuscript (this, however, does not mean that this tool was not
actually used). When the journal websites of the 46 journals that
published the included papers were searched in September 2008,
only 10 of them (22%) required the authors to use STARD when
submitting diagnostic accuracy study manuscripts.
Assessment of the Methodological Quality Using
QUADAS
The overall results of the quality assessment using QUADAS, as
well as the results after stratification by disease and year of
publication are presented in Tables 3 and 4.
The majority of studies used an adequate reference standard test
(96%), and did not suffer from incorporation and partial or
differential verification biases (98 and 92%, respectively). Reference
standard tests considered ‘‘adequate’’ for TB, malaria and HIV
were, respectively, sputum culture, blood smear examination and
ELISAand/orWesternBlot.Nevertheless,all90studies included in
this systematic review had at least one design flaw. The most
commonly noted problems were associated with poor description of
test execution, withdrawal of patients, and interpretation and
reporting of test results.
Quality items that were reported in less than 25% of the studies
included description of withdrawals (6%), adequate description of
the reference test execution (10%), absence of index test review
bias (19%), report of uninterpretable results (22%), and absence of
reference test review bias (24%). Two other quality items were
clearly described in less than 50% of the papers: index test
execution (28%) and absence of clinical review bias (38%). Finally,
a clear description of selection criteria and adequacy of spectrum
composition, which are essential quality items for diagnostic
accuracy studies, were reported in only 51 and 62% of studies,
respectively.
Specific problems with some quality items were detected after
we stratified the studies by disease (TB, malaria and HIV) and year
of publication. In TB and HIV diagnostic accuracy studies, a clear
description of selection criteria was present in less than 50% of
time (47 and 48%, respectively). Moreover, the same item was
reported in only 48% of the study sample published in 2006.
Furthermore, the results stratified by disease showed that HIV
diagnostic accuracy studies met fewer of the methodological
quality criteria when compared to those of TB and malaria. HIV
studies were affected by higher prevalence of important biases such
as partial (19%) and differential (37%) verification, incorporation
(7%) and clinical review (70%) biases.
Finally, when the results were analyzed according to year of
publication, we observed that in 2006, compared to previous years,
a greater number of studies adequately described the index (37%)
Table 2. Characteristics of the studies included (N=90).
Characteristic Frequency (%)
Disease
Tuberculosis 45 (50)
Malaria 18 (20)
HIV 27 (30)
Studies’ origin*
Africa 16
Asia 29
Australia and Oceania 01
Europe 27
North America 11
South America 06
Number of patients per study
Median (interquartile range) 209 (110–555)
Number of studies with industry involvement 39 (43)
Number of studies with conflict of interest 38 (42)
Year of publication
2004 42 (47)
2005 21 (23)
2006 27 (30)
Number of journals where included studies were
published
46
*The total number of countries is not 90 because there were some studies that
were performed in more than one country.
doi:10.1371/journal.pone.0007753.t002
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(11%). These numbers, however, can still be considered very low.
Assessment of the Quality of Report Using STARD
Tables 5 and 6 present the overall and stratified results (by
disease and year of publication) in detail. No study fulfilled all the
25 items of STARD checklist. Overall, the major reporting
problems encountered were in the sections about description of
participants, test and statistical methods, and reporting of results.
Nine STARD items were reported in less than 25% of the
studies: methods for calculation and estimates of test reproduc-
ibility (0%), adverse effects of the diagnostic tests (1%), estimates of
diagnostic accuracy between subgroups (10%), distribution of
severity of disease/other diagnoses in study participants (11%),
number of eligible patients who did not participate in the study
(14%), blinding of the test readers (16%), and description of the
team executing the test and management of indeterminate,
invalid/outlier results (both 17%).
Two other STARD items were poorly reported (less than 50%
of time): participant sampling method (31%) and statistical
methods to calculate diagnostic accuracy and uncertainty/
precision (47%). When specifically analyzing the reporting of
results’ uncertainty, we observed that only 22 of the studies (24%)
presented 95% confidence intervals.
When stratifying the studies by disease, HIV diagnostic accuracy
studies met fewer of the reporting standards compared to those of
TB and malaria diagnostics. Reports of HIV diagnostic accuracy
studies failed, more frequently, to describe 5 out of 8 reporting items
considered essential by our group: sampling strategies used
(reported in 22% of studies), reference standard test (reported in
93% of HIV studies compared to 100% in TB and malaria studies),
data collection methods (reported in 78% of studies), blinding
(reported in 11% of studies – same as malaria) and proportion of
eligible patients that did not participate in the study (reported in
only7% of studies).The 3 other reportingitems considered essential
were inclusion and exclusion criteria, participant recruitment and
Table 3. Assessment of methodological quality using QUADAS* stratified by disease.
QUADAS item(scored as ‘‘Yes’’) Disease Total
Tuberculosis (N=45) Malaria (N=18) HIV (N=27) (N=90)
n( % ) n( % ) n( % ) n( % )
QUADAS 1
Adequate spectrum composition 26 (58) 13 (72) 17 (63) 56 (62)
QUADAS 2
Clear description of selection criteria 21 (47) 12 (67) 13 (48) 46 (51)
QUADAS 3
Adequate reference standard 44 (98) 18 (100) 24 (89) 86 (96)
QUADAS 4
Absence of disease progression bias 42 (93) 15 (83) 21 (78) 78 (87)
QUADAS 5
Absence of partial verification bias 44 (98) 17 (94) 22 (81) 83 (92)
QUADAS 6
Absence of differential verification bias 42 (93) 17 (94) 17 (63) 76 (84)
QUADAS 7
Absence of incorporation bias 45 (100) 18 (100) 25 (93) 88 (98)
QUADAS 8
Adequate description of the index test execution 15 (33) 3 (17) 7 (26) 25 (28)
QUADAS 9
Adequate description of the reference test execution 6 (13) 2 (11) 1 (4) 9 (10)
QUADAS 10
Absence of index test review bias 6 (13) 5 (28) 6 (22) 17 (19)
QUADAS 11
Absence of reference test review bias 7 (16) 8 (44) 7 (26) 22 (24)
QUADAS 12
Absence of clinical review bias 14 (31) 12 (67) 8 (30) 34 (38)
QUADAS 13
Report of uninterpretable results 9 (20) 1 (6) 10 (37) 20 (22)
QUADAS 14
Description of withdrawals 3 (7) 1 (6) 1 (4) 5 (6)
*Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in
systematic reviews. BMC Medical Research Methodology 2003;3:25.
doi:10.1371/journal.pone.0007753.t003
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population.
Analysis by year of publication, revealed that in 2006, a greater
number of studies reported the recruitment strategies used (63%),
technical specifications of material and methods (100%), charac-
teristics of study population (70%), number of eligible patients that
did not undergo index/reference standard test (24%), distribution
of severity of disease (24%) and estimate of diagnostic accuracy
and 95% confidence intervals (100%) compared to previous years.
However, it is important to highlight that the more frequent
reporting of items such as description of material and methods
does not mean that the quality of the report was adequate.
Discussion
TB, malaria and HIV are major killers with enormous global
burden. High-quality evidence on diagnostics is critical for the
development of evidence-based policies on diagnosis, and,
ultimately, for effective control of these global epidemics.[23] In
this study, we evaluated the methodological quality and reporting
quality of recently published diagnostic accuracy studies in TB,
HIV and malaria.
Our results show that diagnostic studies on TB, malaria and
HIV commercial tests published between 2004 and 2006 had
moderate to low methodological quality and were often poorly
reported. Sources of bias and variation were present in all the
studies, and important criteria for determining the presence of bias
were often either not mentioned or unclearly reported. At least for
TB and malaria, these results are consistent with previous
observations made by several researchers.[8,24,25,26]
Most worrisome is the fact that essential methodological
elements, such as selection of a representative population and
blinding, were not used and/or not reported by many researchers.
Furthermore, only a small proportion of the studies adequately
described the execution of both reference (10%) and index (28%)
tests, and no study reported on reproducibility. The implications of
the under-reporting of these elements are several. For example, the
value of sensitivity and specificity estimates are unclear in the
Table 4. Assessment of methodological quality using QUADAS* stratified by year of publication.
QUADAS item (scored as ‘‘Yes’’) Year Total
2004 (N=42) 2005 (N=21) 2006 (N=27) (N=90)
n( % ) n( % ) n( % ) n( % )
QUADAS 1
Adequate spectrum composition 26 (62) 14 (67) 16 (59) 56 (62)
QUADAS 2
Clear description of selection criteria 21 (50) 12 (57) 13 (48) 46 (51)
QUADAS 3
Adequate reference standard 41 (98) 20 (95) 25 (93) 86 (96)
QUADAS 4
Absence of disease progression bias 38 (91) 16 (76) 24 (89) 78 (87)
QUADAS 5
Absence of partial verification 40 (95) 17 (81) 26 (96) 83 (92)
QUADAS 6
Absence of differential verification bias 36 (86) 16 (76) 24 (89) 76 (84)
QUADAS 7
Absence of incorporation bias 42 (100) 19 (91) 27 (100) 88 (98)
QUADAS 8
Adequate description of the index test execution 11 (26) 4 (19) 10 (37) 25 (28)
QUADAS 9
Adequate description of the reference test execution 3 (7) 0 (0) 6 (22) 9 (10)
QUADAS 10
Absence of index test review bias 10 (24) 4 (19) 3 (11) 17 (19)
QUADAS 11
Absence of reference test review bias 10 (24) 3 (14) 9 (33) 22 (24)
QUADAS 12
Absence of clinical review bias 17 (41) 7 (33) 10 (37) 34 (38)
QUADAS 13
Report of uninterpretable results 10 (24) 4 (19) 6 (22) 20 (22)
QUADAS 14
Description of withdrawals 2 (5) 0 (0) 3 (11) 5 (6)
*Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in
systematic reviews. BMC Medical Research Methodology 2003;3:25.
doi:10.1371/journal.pone.0007753.t004
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Section and Topic in the STARD checklist (scored as ‘‘Reported’’) Disease Total
TB
(N=45)
Malaria
(N=18)
HIV
(N=27) (N=90)
n( % ) n( % ) n( % ) n( % )
TITLE/ABSTRACT/KEYWORDS
Identify the article as a study of diagnostic accuracy (recommend MeSH heading ‘sensitivity and specificity’). 44 (98) 18 (100) 27 (100) 89 (99)
INTRODUCTION
State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between
tests or across participant groups.
44 (98) 17 (94) 25 (93) 86 (96)
METHODS (describe)
Participants
The study population: the inclusion and exclusion criteria, setting and locations where the data were collected. 30 (67) 17 (94) 23 (85) 70 (78)
Participant recruitment: was recruitment based on presenting symptoms, results from previous tests, or the fact
that the participants had received the index tests or the reference standard?
c
28 (62) 13 (29) 13 (48) 54 (60)
Participant sampling: was the study population a consecutive series of participants defined by the selection criteria
in the previous 2 items? If not, specify how participants were further selected.
1
14 (31) 8 (44) 6 (22) 28 (31)
Data collection: was data collection planned before the index test and reference standard were performed
(prospective study) or after (retrospective study)?
h
38 (84) 16 (89) 21 (78) 75 (83)
Test methods
The reference standard and its rationale. 45 (100) 18 (100) 25 (93) 88 (98)
Technical specifications of material and methods involved including how and when measurements were taken,
and/or cite references for index tests and reference standard.
44 (98) 16 (89) 21 (78) 81 (90)
Definition of and rationale for the units, cutoffs, and/or categories of the results of the index tests and the
reference standard.
41 (91) 16 (89) 18 (67) 75 (83)
The number, training, and expertise of the persons executing and reading the index tests and the reference standard. 3 (7) 7 (39) 5 (19) 15 (17)
Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the
other test and describe any other clinical information available to the readers.
5 (11) 6 (33) 3 (11) 14 (16)
Statistical methods
Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to
quantify uncertainty (e.g., 95% confidence intervals).
16 (36) 12 (67) 14 (52) 42 (47)
Methods for calculating test reproducibility, if done. 0 (0) 0 (0) 0 (0) 0 (0)
RESULTS (report)
Participants
When study was done, including beginning and ending dates of recruitment. 34 (76) 16 (89) 16 (59) 66 (73)
Clinical and demographic characteristics of the study population (e.g., age, sex, spectrum of presenting symptoms,
comorbidity, current treatments, recruitment centers).
27 (60) 13 (29) 19 (70) 59 (66)
The number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the
reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended).
7 (16) 4 (22) 2 (7) 13 (14)
Test results
Time interval from the index tests to the reference standard, and any treatment administered between. 36 (80) 13 (29) 18 (67) 67 (74)
Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in
participants without the target condition.
6 (13) 1 (6) 3 (11) 10 (11)
A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the
reference standard; for continuous results, the distribution of the test results by the results of the reference standard.
45 (100) 18 (100) 26 (96) 89 (99)
Any adverse events from performing the index tests or the reference standard. 1 (2) 0 (0) 0 (0) 1 (1)
Estimates
Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., 95% confidence intervals). 43 (96) 17 (94) 27 (100) 87 (97)
How indeterminate results, missing responses, and outliers of the index tests were handled. 8 (18) 0 (0) 7 (26) 15 (17)
Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done. 1 (2) 2 (11) 6 (22) 9 (10)
Estimates of test reproducibility, if done. 0 (0) 0 (0) 0 (0) 0 (0)
DISCUSSION
Discuss the clinical applicability of the study findings. 44 (98) 18 (100) 27 (100) 89 (99)
TB = tuberculosis MeSH = medical subject heading
c = recruitment based on symptoms
1 = consecutive sampling
h = prospective study.
*Adapted from Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern
Med 2003;138:40-4.
doi:10.1371/journal.pone.0007753.t005
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Section and Topic in the STARD checklist (scored as ‘‘Reported’’) Year Total
2004
(N=42)
2005
(N=21)
2006
(N=27) (N=90)
n( % ) n( % ) n( % ) n( % )
TITLE/ABSTRACT/KEYWORDS
Identify the article as a study of diagnostic accuracy (recommend MeSH heading ‘sensitivity and specificity’). 42 (100) 21 (100) 26 (96) 89 (99)
INTRODUCTION
State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between
tests or across participant groups.
39 (93) 21 (100) 26 (96) 86 (96)
METHODS (describe)
Participants
The study population: the inclusion and exclusion criteria, setting and locations where the data were collected. 34 (81) 17 (81) 19 (70) 70 (78)
Participant recruitment: was recruitment based on presenting symptoms, results from previous tests, or the fact that
the participants had received the index tests or the reference standard?
c
24 (57) 13 (62) 17 (63) 54 (60)
Participant sampling: was the study population a consecutive series of participants defined by the selection criteria
in the previous 2 items? If not, specify how participants were further selected.
1
14 (33) 8 (38) 6 (22) 28 (31)
Data collection: was data collection planned before the index test and reference standard were performed
(prospective study) or after (retrospective study)?
h
36 (86) 18 (86) 21 (78) 75 (83)
Test methods
The reference standard and its rationale. 45 (100) 18 (100) 25 (93) 88 (98)
Technical specifications of material and methods involved including how and when measurements were taken,
and/or cite references for index tests and reference standard.
41 (98) 20 (95) 27 (100) 88 (98)
Definition of and rationale for the units, cutoffs, and/or categories of the results of the index tests and the reference standard. 38 (91) 19 (91) 24 (89) 81 (90)
The number, training, and expertise of the persons executing and reading the index tests and the reference standard. 34 (81) 17 (81) 24 (89) 75 (83)
Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the
other test and describe any other clinical information available to the readers.
8 (19) 3 (14) 4 (15) 15 (17)
Statistical methods
Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify
uncertainty (e.g., 95% confidence intervals).
17 (41) 11 (52) 14 (52) 42 (47)
Methods for calculating test reproducibility, if done. 0 (0) 0 (0) 0 (0) 0 (0)
RESULTS (report)
Participants
When study was done, including beginning and ending dates of recruitment. 34 (81) 13 (62) 19 (70) 66 (73)
Clinical and demographic characteristics of the study population (e.g., age, sex, spectrum of presenting symptoms,
comorbidity, current treatments, recruitment centers).
29 (69) 13 (62) 17 (70) 59 (66)
The number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the
reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended).
7 (17) 2 (10) 4 (24) 13 (14)
Test results
Time interval from the index tests to the reference standard, and any treatment administered between. 33 (79) 14 (67) 20 (74) 67 (74)
Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants
without the target condition.
4 (10) 2 (10) 4 (24) 10 (11)
A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the
reference standard; for continuous results, the distribution of the test results by the results of the reference standard.
42 (100) 20 (95) 27 (100) 89 (99)
Any adverse events from performing the index tests or the reference standard. 1 (2) 0 (0) 0 (0) 1 (1)
Estimates
Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., 95% confidence intervals). 40 (95) 20 (95) 27 (100) 87 (97)
How indeterminate results, missing responses, and outliers of the index tests were handled. 8 (18) 4 (19) 3 (11) 15 (17)
Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done. 5 (12) 2 (10) 2 (7) 9 (10)
Estimates of test reproducibility, if done. 0 (0) 0 (0) 0 (0) 0 (0)
DISCUSSION
Discuss the clinical applicability of the study findings. 41 (98) 21 (100) 27 (100) 89 (99)
MeSH = Medical Subject Heading
c = recruitment based on symptoms
1 = consecutive sampling
h = prospective study.
*Adapted from Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern
Med 2003;138:40-4.
doi:10.1371/journal.pone.0007753.t006
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if a reference standard is imperfect or poorly done, then this can
potentially under-estimate or over-estimate the accuracy of a test.
If the index test is poorly described, other researchers cannot
replicate the study results (although this is less of an issue with
standardized commercial kits).
Strengths and Limitations
The major strength of this study is the systematic search for
diagnostic accuracy studies via PubMed and EMBASE, two of the
most widely used health literature databases. Furthermore, we
used rigorous methods to select studies and abstract data, the latter
independently conducted by two trained researchers.
The use of both QUADAS and STARD to evaluate diagnostic
accuracy studies is also a strength of this systematic review. Both
tools were developed by experts with the respective aims of
assessing the quality of diagnostic studies included in systematic
reviews and improve the quality of reporting of diagnostic studies
in general. Furthermore, QUADAS and STARD are well
standardized and easy to implement.[21,27] The complementary
aspect of these tools also allowed us to have a deeper
understanding of the current methodological and reporting quality
of these studies. For example, for the item ‘‘reference test
execution’’, while more than 90% of the studies reported the
reference test execution (STARD), only less than 25% of them did
it in an adequate and clear manner (QUADAS).
An important limitation of our study is that we did not compare
our results to a sample of studies published before the publication
of QUADAS and STARD instruments (i.e., prior to 2003).
Consequently, we can provide information about the current
quality of methods and reporting of diagnostic studies, but not
about changes in quality or reporting over time.
Wilczynski and colleagues compared the quality of report of
papers published in journals that endorsed STARD versus those
that did not (i.e., journals that published or not the STARD
statement in 2003).[28] Studies were also compared according to
year of publication (2001, 2002, 2004 and 2005). The results
showed that the quality of report was not affected by the type of
journal, and that it remained similar over time.
Another limitation of our study is the fact that we decided to
only record information that was clearly stated in the paper,
coding as ‘‘not reported’’ when data were not available. Thus, it
may be possible that methodological quality items were met in the
actual study, but not reported. Because we did not contact all the
authors, we were unable to resolve this issue.
Implications
Poor quality of diagnostic studies is a recognized problem. After
the publication of QUADAS and STARD in 2003, the
expectation was that the methodological quality of diagnostic
studies, and the quality of their reporting, would improve over the
years. Unfortunately, this objective seems to be far from being
achieved, at least with respect to diagnostic studies on major
infectious diseases.
Our results suggest that STARD is probably not used by
researchers as often as expected or desired, at least in the field of
infectious diseases. Furthermore, we have shown that, based on
the results of a search performed in September 2008, only 22% of
the journals in our study sample required authors to use STARD
when submitting a diagnostic accuracy manuscript for publication.
Consequently, we hypothesize that fact that not many journals
require authors to use STARD may be one of the causes behind
the lack of improvement of reporting of diagnostic studies over
time. When we repeating this search in October 2009, we
observed that this number increased to 50%, probably due to the
adoption of the Uniform Requirements for Manuscripts Submitted to
Biomedical Journal (URM) created by the International Committee
of Medical Journal Editors (ICMJE), which recommends authors
to use ‘‘reporting guidelines relevant to their specific research
design’’, such as STARD.[29] Despite the substantial increase in
the proportion of journals recommending the use of STARD, this
proportion is still far from ideal.
Decreasing the burden of TB, malaria and HIV is a priority
worldwide, and the provision of universal, high-quality and
affordable diagnostic tests to affected populations is the first key
step to achieve this goal. Regulatory authorities, policy makers and
healthcare professionals frequently use diagnostic accuracy studies
to decide which test should be implemented in a particular setting.
However, choices based on biased study results may lead to
detrimental consequences.
Lack of methodological rigour in diagnostic trials is a cause for
concern as it may prove to be a major hurdle for effective
application of diagnostics in controlling TB, malaria and HIV.
Depending on how the presence of bias affects the estimates of
diagnostic accuracy, a large number of patients could be harmed
by not being properly diagnosed and consequently not receiving
adequate care. [16,17] Furthermore, biased results from poorly
designed studies can lead to premature or misguided adoption of
tests that may have little or no clinical and public health relevance,
and result in incorrect diagnosis and adverse consequences for the
patient and/or the healthcare service. A good example of this is
widespread use of serological, antibody tests for TB, when all the
evidence suggests that they have poor accuracy and have no
clinical role.[8] The situation is exacerbated by the fact that most
developing countries have poor or nonexistent regulatory
mechanisms for marketing and post-marketing surveillance of
diagnostics.[30]
Thus, due to the negative implications that biased studies can
present, efforts are urgently needed to improve quality of
diagnostic research as well as quality of reporting. The more
frequent use of tools such as QUADAS and STARD could aid in
this process. While not designed with this intent, QUADAS, for
example, could be used by researchers as a guideline when
designing diagnostic studies, as it describes all the quality elements
that should be present in this type of study. QUADAS can also be
used as an educational tool, to help train researches in improving
research design. STARD can be very useful at the manuscript
development stage. However, because voluntary use of tools such
as QUADAS and STARD is likely to be limited, their widespread
use will probably only happen if more journals explicitly required
and mandated authors to use these tools.
While improving diagnostic accuracy studies is a good starting
point, efforts must also be made to go beyond test accuracy and
generate evidence on patient-important outcomes that can inform
policy and guideline development. For example, much of the
existing evidence-base in TB is focused on test accuracy [8,31].
There are limited data on outcomes such as accuracy of diagnostic
algorithms (rather than single tests) and their relative contributions
to the health care system, incremental value of new tests, impact of
new tests on clinical decision-making and therapeutic choices,
cost-effectiveness in routine programmatic settings, and impact on
patient-important outcomes. Future diagnostic studies must
attempt to collect data on these outcomes and not merely focus
on test accuracy.
In conclusion, our data suggests that recently published
diagnostic studies on commercial tests for TB, malaria and HIV
are of moderate to low quality and are poorly reported. Essential
methodological and design elements were often either not reported
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QUADAS and STARD may be necessary to improve methodo-
logical quality and reporting of future diagnostic accuracy studies
in infectious diseases. This may happen only when more journals
require authors to use instruments such as STARD.
Acknowledgments
The authors thank Dr. Jesse Papenburg for his thoughtful review of this
manuscript.
Author Contributions
Conceived and designed the experiments: ND AR MP. Performed the
experiments: PF NPP. Analyzed the data: PF IS ND MP. Wrote the paper:
PF NPP IS ND AR MP. Obtained funding: MP AR. Provided supervision:
MP.
References
1. Aregawi M, Cibulskis R, Williams R, Dye C (2008) World malaria report 2008.
Geneva, Switzerland: World Health Organization.
2. Dye C, Floyd K, Uplekar M (2008) Global tuberculosis control: surveillance,
planning, financing: WHO report 2008. Geneva, Switzerland: World Health
Organization.
3. Joint United Nations Programme on HIV/AIDS (2008) Report on the global
AIDS epidemic. Geneva, Switzerland: UNAIDS.
4. The Global Fund to Fight AIDS Tberculosis and Malaria (2009) The Global
Fund to Fight AIDS, Tuberculosis and Malaria. ;http://www.theglobalfund.
org/en/(Access date: August 7,2009).
5. Peeling RW, Holmes KK, Mabey D, Ronald A (2006) Rapid tests for sexually
transmitted infections (STIs): the way forward. Sex Transm Inf 82: v1–v6.
6. Hopkins H, Asiimwe C, Bell D (2009) Access to antimalarial therapy: accurate
diagnosis is essential to achieving long term goals. BMJ 339: b2606.
7. World Health Organization (2008) WHO policy statement: molecular line probe
assays for rapid screening of patients at risk of multidrug-resistant tuberculosis.
;http://www.who.int/tb/features_archive/policy_statement.pdf (Access date:
August 3,2009).
8. Pai M, Ramsay A, O’Brien R (2008) Evidence-Based Tuberculosis Diagnosis.
PLoS Medicine 5: e156.
9. Pai M, O’Brien R (2008) New diagnostics for latent and active tuberculosis: state
of the art and future prospects. Semin Respir Crit Care Med 29: 560–568.
10. World Health Organization (2007) New WHO polices: the use of liquid medium
for culture and DST. http://www.who.int/tb/dots/laboratory/policy/en/
index3.htm (Access date: August 3,2009).
11. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, et al. (2008)
Grading quality of evidence and strength of recommendations for diagnostic
tests and strategies. BMJ 336: 1106–1110.
12. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, et al. (2004) Grading
quality of evidence and strength of recommendations. BMJ 328: 1490-.
13. Reid MC, Lachs MS, Feinstein AR (1995) Use of methodological standards in
diagnostic test research. Getting better but still not good. JAMA 274: 645–651.
14. Rama KRBS, Poovali S, Apsingi S (2006) Quality of reporting of orthopaedic
diagnostic accuracy studies is suboptimal. Clinical Orthopaedics & Related
Research 447: 237–246.
15. Siddiqui MAR, Azuara-Blanco A, Burr J (2005) The quality of reporting of
diagnostic accuracy studies published in ophthalmic journals. British Journal of
Ophthalmology 89: 261–265.
16. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, et al. (1999)
Empirical Evidence of Design-Related Bias in Studies of Diagnostic Tests.
JAMA 282: 1061–1066.
17. Rutjes AWS, Reitsma JB, Di Nisio M, Smidt N, van Rijn JC, et al. (2006)
Evidence of bias and variation in diagnostic accuracy studies. CMAJ 174:
469–476.
18. Westwood M, Whiting P, Kleijnen J (2005) How does study quality affect the
results of a diagnostic meta-analysis? BMC Medical Research Methodology 5:
20.
19. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, et al. (2003)
Towards complete and accurate reporting of studies of diagnostic accuracy: The
STARD Initiative. Ann Intern Med 138: 40–44.
20. Whiting P, Rutjes A, Reitsma J, Bossuyt P, Kleijnen J (2003) The development
of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy
included in systematic reviews. BMC Medical Research Methodology 3: 25.
21. Whiting P, Weswood M, Rutjes A, Reitsma J, Bossuyt P, et al. (2006) Evaluation
of QUADAS, a tool for the quality assessment of diagnostic accuracy studies.
BMC Medical Research Methodology 6: 9.
22. Standards for the Reporting of Diagnostic Accuracy Studies Group (2008)
STARD statement: news. http://www.stard-statement.org/(Access date: August
7,2009).
23. Mabey D, Peeling RW, Ustianowski A, Perkins MD (2004) Tropical infectious
diseases: Diagnostics for the developing world. Nat Rev Micro 2: 231–240.
24. Small PM, Perkins MD (2000) More rigour needed in trials of new diagnostic
agents for tuberculosis. The Lancet 356: 1048–1049.
25. Cot M (2005) Clinical research on malaria: what for the future? Rev Epidemiol
Sante Publique 53: 291–297.
26. Pai M, O’Brien R (2006) Tuberculosis diagnostics trials: do they lack
methodological rigor? Expert Review of Molecular Diagnostics 6: 509–514.
27. Smidt N, Rutjes A, van der Windt D, Ostelo R, Bossuyt P, et al. (2006)
Reproducibility of the STARD checklist: an instrument to assess the quality of
reporting of diagnostic accuracy studies. BMC Medical Research Methodology
6: 12.
28. Wilczynski NL (2008) Quality of reporting of diagnostic accuracy studies: no
change since STARD statement publication–before-and-after study. Radiology
248: 817–823.
29. International Committee of Medical Journal Editors (2008) International
Committee of Medical Journal Editors (ICMJE). Uniform Requirements for
Manuscripts Submitted to Biomedical Journal.
30. Peeling RW, Smith PG, Bossuyt PMM (2006) A guide for diagnostic evaluations.
Nat Rev Micro 4: S2–S6.
31. Pai M, Ramsay A, O’Brien R (2009) Comprehensive new resource for evidence-
based TB diagnosis. Expert Rev Mol Diagn 9(7): 637–9.
Quality of Diagnostic Studies
PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7753